论文部分内容阅读
目的评价自体造血干细胞移植((AHSCT)治疗恶性血液病的临床疗效。方法回顾性分析42例行AHSCT的患者资料,其中标危病例为27例,高危病例为15例。结果除2例在造血重建过程中死亡外,余40例患者均获造血重建。该组患者3年和5年总生存率(OS)分别是(82.3±12.1)%和(77.2±9.6)%,3年和5年无病生存率(DFS)分别是(71.8±8.3)%和(69.2±9.2)%。标危与高危两组之间的5年OS分别为(96.1±4.1)%和(49.1±16.2)%,DFS分别为(92.1±4.2)%和(28.2±13.1)%,累积复发率分别为(19.1±8.2)%和(50.1±12.1)%,三者均有显著性意义(P<0.001)。AHSCT后维持治疗组的复发率较无维持治疗组显著降低(P<0.001)。结论AHSCT是治疗恶性血液病的有效手段,移植前患者的疾病状态是影响移植后复发的主要因素,移植后的维持治疗能有效地降低复发率。
Objective To evaluate the clinical efficacy of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of hematologic malignancies.Methods The data of 42 patients with AHSCT were retrospectively analyzed, including 27 cases of standard risk and 15 cases of high risk.Results In 2 cases, 40 patients were hematopoietic reconstructed except for the death during reconstruction.The overall OS rates in this group were (82.3 ± 12.1)% and (77.2 ± 9.6)% at 3 years and 5 years respectively The prevalence of disease-free survival (DFS) was (71.8 ± 8.3)% and (69.2 ± 9.2)%, respectively. The 5-year OS was 96.1 ± 4.1% and 49.1 ± 16.2% , And the DFS were (92.1 ± 4.2)% and (28.2 ± 13.1)%, respectively. The cumulative recurrence rates were (19.1 ± 8.2)% and (50.1 ± 12.1)% respectively, all of which were significant (P <0.001). The recurrence rate of AHSCT patients after maintenance therapy was significantly lower than that of patients without maintenance therapy (P <0.001) .Conclusion AHSCT is an effective treatment for hematologic malignancies, and the disease status before transplantation is the main factor that affects the recurrence after transplantation. Maintenance treatment can effectively reduce the recurrence rate.